News Focus
News Focus
Post# of 257259
Next 10
Followers 842
Posts 122798
Boards Moderated 10
Alias Born 09/05/2002

Re: iwfal post# 172949

Monday, 01/20/2014 3:16:15 PM

Monday, January 20, 2014 3:16:15 PM

Post# of 257259

XOMA—[Gevokizumab] probably worth a 20 to 40 percent (WAG) premium once more broadly approved in general NIU.

I don’t understand what you mean by a 20-40% premium in this context—please clarify.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now